YAP1和其他转录因子的表达促进了合并小细胞肺癌的细胞系可塑性

IF 3.4 2区 医学 Q1 PATHOLOGY
Naoe Jimbo, Chiho Ohbayashi, Tomomi Fujii, Maiko Takeda, Suguru Mitsui, Yugo Tanaka, Tomoo Itoh, Yoshimasa Maniwa
{"title":"YAP1和其他转录因子的表达促进了合并小细胞肺癌的细胞系可塑性","authors":"Naoe Jimbo,&nbsp;Chiho Ohbayashi,&nbsp;Tomomi Fujii,&nbsp;Maiko Takeda,&nbsp;Suguru Mitsui,&nbsp;Yugo Tanaka,&nbsp;Tomoo Itoh,&nbsp;Yoshimasa Maniwa","doi":"10.1002/2056-4538.70001","DOIUrl":null,"url":null,"abstract":"<p>Lineage plasticity in small cell lung carcinoma (SCLC) causes therapeutic difficulties. This study aimed to investigate the pathological findings of plasticity in SCLC, focusing on combined SCLC, and elucidate the involvement of YAP1 and other transcription factors. We analysed 100 surgically resected SCLCs through detailed morphological observations and immunohistochemistry for YAP1 and other transcription factors. Component-by-component next-generation sequencing (<i>n</i> = 15 pairs) and immunohistochemistry (<i>n</i> = 35 pairs) were performed on the combined SCLCs. Compared with pure SCLCs (<i>n</i> = 65), combined SCLCs (<i>n</i> = 35) showed a significantly larger size, higher expression of NEUROD1, and higher frequency of double-positive transcription factors (<i>p</i> = 0.0009, 0.04, and 0.019, respectively). Notably, 34% of the combined SCLCs showed morphological mosaic patterns with unclear boundaries between the SCLC and its partner. Combined SCLCs not only had unique histotypes as partners but also represented different lineage plasticity within the partner. NEUROD1-dominant combined SCLCs had a significantly higher proportion of adenocarcinomas as partners, whereas POU2F3-dominant combined SCLCs had a significantly higher proportion of squamous cell carcinomas as partners (<i>p</i> = 0.006 and <i>p</i> = 0.0006, respectively). YAP1 expression in SCLC components was found in 80% of combined SCLCs and 62% of pure SCLCs, often showing mosaic-like expression. Among the combined SCLCs with component-specific analysis, the identical <i>TP53</i> mutation was found in 10 pairs, and the identical <i>Rb1</i> abnormality was found in 2 pairs. On immunohistochemistry, the same abnormal p53 pattern was found in 34 pairs, and Rb1 loss was found in 24 pairs. In conclusion, combined SCLC shows a variety of pathological plasticity. Although combined SCLC is more plastic than pure SCLC, pure SCLC is also a phenotypically plastic tumour. The morphological mosaic pattern and YAP1 mosaic-like expression may represent ongoing lineage plasticity. This study also identified the relationship between transcription factors and partners in combined SCLC. Transcription factors may be involved in differentiating specific cell lineages beyond just ‘neuroendocrine’.</p>","PeriodicalId":48612,"journal":{"name":"Journal of Pathology Clinical Research","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/2056-4538.70001","citationCount":"0","resultStr":"{\"title\":\"The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma\",\"authors\":\"Naoe Jimbo,&nbsp;Chiho Ohbayashi,&nbsp;Tomomi Fujii,&nbsp;Maiko Takeda,&nbsp;Suguru Mitsui,&nbsp;Yugo Tanaka,&nbsp;Tomoo Itoh,&nbsp;Yoshimasa Maniwa\",\"doi\":\"10.1002/2056-4538.70001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Lineage plasticity in small cell lung carcinoma (SCLC) causes therapeutic difficulties. This study aimed to investigate the pathological findings of plasticity in SCLC, focusing on combined SCLC, and elucidate the involvement of YAP1 and other transcription factors. We analysed 100 surgically resected SCLCs through detailed morphological observations and immunohistochemistry for YAP1 and other transcription factors. Component-by-component next-generation sequencing (<i>n</i> = 15 pairs) and immunohistochemistry (<i>n</i> = 35 pairs) were performed on the combined SCLCs. Compared with pure SCLCs (<i>n</i> = 65), combined SCLCs (<i>n</i> = 35) showed a significantly larger size, higher expression of NEUROD1, and higher frequency of double-positive transcription factors (<i>p</i> = 0.0009, 0.04, and 0.019, respectively). Notably, 34% of the combined SCLCs showed morphological mosaic patterns with unclear boundaries between the SCLC and its partner. Combined SCLCs not only had unique histotypes as partners but also represented different lineage plasticity within the partner. NEUROD1-dominant combined SCLCs had a significantly higher proportion of adenocarcinomas as partners, whereas POU2F3-dominant combined SCLCs had a significantly higher proportion of squamous cell carcinomas as partners (<i>p</i> = 0.006 and <i>p</i> = 0.0006, respectively). YAP1 expression in SCLC components was found in 80% of combined SCLCs and 62% of pure SCLCs, often showing mosaic-like expression. Among the combined SCLCs with component-specific analysis, the identical <i>TP53</i> mutation was found in 10 pairs, and the identical <i>Rb1</i> abnormality was found in 2 pairs. On immunohistochemistry, the same abnormal p53 pattern was found in 34 pairs, and Rb1 loss was found in 24 pairs. In conclusion, combined SCLC shows a variety of pathological plasticity. Although combined SCLC is more plastic than pure SCLC, pure SCLC is also a phenotypically plastic tumour. The morphological mosaic pattern and YAP1 mosaic-like expression may represent ongoing lineage plasticity. This study also identified the relationship between transcription factors and partners in combined SCLC. Transcription factors may be involved in differentiating specific cell lineages beyond just ‘neuroendocrine’.</p>\",\"PeriodicalId\":48612,\"journal\":{\"name\":\"Journal of Pathology Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/2056-4538.70001\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pathology Clinical Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/2056-4538.70001\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pathology Clinical Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/2056-4538.70001","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

小细胞肺癌(SCLC)的细胞系可塑性给治疗带来了困难。本研究旨在研究SCLC可塑性的病理结果,重点关注合并SCLC,并阐明YAP1和其他转录因子的参与。我们通过详细的形态学观察和YAP1及其他转录因子的免疫组化对100例手术切除的SCLC进行了分析。对合并的SCLCs进行了逐组分新一代测序(n = 15对)和免疫组化(n = 35对)。与纯合SCLCs(n = 65)相比,合并SCLCs(n = 35)的体积明显更大,NEUROD1的表达量更高,转录因子双阳性的频率更高(p = 0.0009、0.04和0.019,分别为0.0009、0.04和0.019)。值得注意的是,34%的合并 SCLC 表现出形态学镶嵌模式,SCLC 及其伙伴之间的界限不清。合并的 SCLC 不仅作为伴侣具有独特的组织型,而且还代表了伴侣内部不同的系可塑性。NEUROD1显性合并SCLC的伴侣中腺癌的比例明显更高,而POU2F3显性合并SCLC的伴侣中鳞状细胞癌的比例明显更高(分别为p = 0.006和p = 0.0006)。在80%的合并SCLC和62%的纯合SCLC中,发现YAP1在SCLC成分中表达,通常呈镶嵌样表达。在进行成分特异性分析的合并 SCLC 中,有 10 对发现了相同的 TP53 突变,2 对发现了相同的 Rb1 异常。免疫组化结果显示,34 对病例中发现了相同的 p53 异常模式,24 对病例中发现了 Rb1 缺失。总之,合并 SCLC 表现出多种病理可塑性。虽然合并 SCLC 比单纯 SCLC 更具可塑性,但单纯 SCLC 也是一种表型可塑性肿瘤。形态学上的镶嵌模式和YAP1镶嵌样表达可能代表了持续的系谱可塑性。这项研究还确定了合并 SCLC 中转录因子与合作伙伴之间的关系。转录因子可能参与了特定细胞系的分化,而不仅仅是 "神经内分泌"。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma

The expression of YAP1 and other transcription factors contributes to lineage plasticity in combined small cell lung carcinoma

Lineage plasticity in small cell lung carcinoma (SCLC) causes therapeutic difficulties. This study aimed to investigate the pathological findings of plasticity in SCLC, focusing on combined SCLC, and elucidate the involvement of YAP1 and other transcription factors. We analysed 100 surgically resected SCLCs through detailed morphological observations and immunohistochemistry for YAP1 and other transcription factors. Component-by-component next-generation sequencing (n = 15 pairs) and immunohistochemistry (n = 35 pairs) were performed on the combined SCLCs. Compared with pure SCLCs (n = 65), combined SCLCs (n = 35) showed a significantly larger size, higher expression of NEUROD1, and higher frequency of double-positive transcription factors (p = 0.0009, 0.04, and 0.019, respectively). Notably, 34% of the combined SCLCs showed morphological mosaic patterns with unclear boundaries between the SCLC and its partner. Combined SCLCs not only had unique histotypes as partners but also represented different lineage plasticity within the partner. NEUROD1-dominant combined SCLCs had a significantly higher proportion of adenocarcinomas as partners, whereas POU2F3-dominant combined SCLCs had a significantly higher proportion of squamous cell carcinomas as partners (p = 0.006 and p = 0.0006, respectively). YAP1 expression in SCLC components was found in 80% of combined SCLCs and 62% of pure SCLCs, often showing mosaic-like expression. Among the combined SCLCs with component-specific analysis, the identical TP53 mutation was found in 10 pairs, and the identical Rb1 abnormality was found in 2 pairs. On immunohistochemistry, the same abnormal p53 pattern was found in 34 pairs, and Rb1 loss was found in 24 pairs. In conclusion, combined SCLC shows a variety of pathological plasticity. Although combined SCLC is more plastic than pure SCLC, pure SCLC is also a phenotypically plastic tumour. The morphological mosaic pattern and YAP1 mosaic-like expression may represent ongoing lineage plasticity. This study also identified the relationship between transcription factors and partners in combined SCLC. Transcription factors may be involved in differentiating specific cell lineages beyond just ‘neuroendocrine’.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pathology Clinical Research
Journal of Pathology Clinical Research Medicine-Pathology and Forensic Medicine
CiteScore
7.40
自引率
2.40%
发文量
47
审稿时长
20 weeks
期刊介绍: The Journal of Pathology: Clinical Research and The Journal of Pathology serve as translational bridges between basic biomedical science and clinical medicine with particular emphasis on, but not restricted to, tissue based studies. The focus of The Journal of Pathology: Clinical Research is the publication of studies that illuminate the clinical relevance of research in the broad area of the study of disease. Appropriately powered and validated studies with novel diagnostic, prognostic and predictive significance, and biomarker discover and validation, will be welcomed. Studies with a predominantly mechanistic basis will be more appropriate for the companion Journal of Pathology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信